Meds CJC-1295

Research digest / Sources

CJC-1295 references, listed in full

Every study cited across this digest, with DOIs and PubMed identifiers. The pharmacokinetic claims trace to the human studies; the mechanism to the bioconjugate and enzymology work.

Back to the researchAbout this digest

How to read this list

These are the CJC-1295 references behind every numbered claim on this site. The human pharmacokinetics rest on Teichman 2006 [1] and Ionescu/Frohman 2006 [3]; the long-acting mechanism on the Jette 2005 bioconjugate study [2]; the once-daily growth normalization on Alba 2006 [4]. The class context comes from the 2024/2025 Nature Reviews Endocrinology review [13].

Where a figure appears more than once across the digest — the 5.8-8.1 day half-life, the 28-day IGF-1 elevation, the 4-fold GH AUC in rats — it traces to the same source each time. The full list follows.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency. (D-Ala2 GHRH analog pharmacology). 1994. ↗
  8. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. ↗
  9. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. (Early GRF(1-29) pharmacokinetic study). 1986. ↗
  10. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. ↗
  11. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers / swine. Pharm Res. 1999. ↗
  12. Modified GRF (1-29) - chemical and pharmacological description (the no-DAC, tetrasubstituted GHRH(1-29) analog distinct from CJC-1295 DAC). Encyclopedic reference. 2024. ↗
  13. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  14. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗